^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    AKT2 inhibitor

    Related drugs:
    Apply
    Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients (NCT01915576)
    Phase 1
    Bayer
    Completed
    Last update posted :
    12/28/2016
    Initiation :
    09/01/2013
    Primary completion :
    07/01/2016
    Completion :
    12/01/2016
    AKT1
    |
    AKT1 E17K • AKT1 mutation
    |
    BAY 1125976